Kornimate/medical-research-clean huggingface dataset:
addressing psychological risk factors underlying smoking persistence in copd patients: the fresh start study

Conditions: Copd; Smoking Cessation; Nicotine Dependence; Tobacco Use; Cigarette Smoking

Summary: chronic obstructive pulmonary disease (copd) is caused primarily by smoking and smoking cessation is the first-line treatment for slowing disease progression. despite this, nearly 50% of copd patients continue to smoke following diagnosis. smokers with copd report high rates of co-occurring conditions - nicotine dependence, depression, and anxiety - which serve as barriers to quitting. the current study will pilot test a behavioral intervention designed to target the common psychological factors underlying these co-occurring conditions and foster smoking cessation among copd patients.

chronic obstructive pulmonary disease (copd) is caused primarily by smoking and smoking cessation is the first-line treatment for slowing disease progression. despite this, nearly 50% of copd patients continue to smoke following diagnosis. smokers with copd report high rates of co-occurring conditions - nicotine dependence, depression, and anxiety - which serve as barriers to quitting. the current study will pilot test a behavioral intervention designed to target the common psychological factors underlying these co-occurring conditions and foster smoking cessation among copd patients. the specific aim is to: aim: develop a multi-component behavioral treatment to address psychological risk factors among copd patients. we will conduct a component analysis using single case design experiments with 15 participants to a) examine the contribution of each treatment component to the behavioral target of smoking for affect regulation, and b) establish proof-of-concept on the clinical endpoint of initial cessation (\>24 hours abstinence).

Eligibility criteria:
inclusion criteria: eligible participants will be males and females who are: * diagnosed with copd (as documented in electronic health record \[ehr\]), * daily cigarette smokers (5 or more cigarettes per day over past 30 days), * intend to quit smoking within the next 60 days, * report at least moderate level of smoking for affective regulation (smq-r coping subscale score 30 or greater), * have access to a smart phone, tablet, or computer, and * are able to communicate fluently in english exclusion criteria: * any concurrent medical or psychiatric condition which would preclude ability to provide informed consent or perform study procedures (e.g., moderate to severe dementia and/or severe, uncontrolled schizophrenia), as determined by the treating physician or study pi.

Keywords: copd smoking cessation nicotine dependence tobacco use cigarette smoking behavioral treatment
immediate implant placement in aggressive periodontitis

Conditions: Periodontitis

Summary: the aim of the present study is to evaluate the health of immediately placed dental implants in aggressive periodontitis patients versus those placed in periodontally healthy individuals in the maxillary esthetic zone.

aggressive periodontitis is an enigmatic periodontal disease that characterized by massive and undeterminable periods of tissue destruction. it gets along well to young individuals with successive periods of disease activity. aggressive bone destruction with limited plaque and calculus deposits usually detected. according to microbial theory, aggregatibacter actinomycetemcomitans (a.a) and p. gingivalis (p. g) were claimed for such a disease. patients of aggressive periodontitis have disturbed esthetic and masticatory function problems. after wards, microbial theory was modified to enroll the genetic background that can be the cause behind the developed body resistance. although the importance of the genetic treatment to improve the body response, it was totally dismissed during the routine periodontal work attributable to high cost effectiveness of the needed genetic analysis especially in developing countries. further researches tried to explain the cause behind the impaired body response. impaired functions of the immune cells and the massive amounts of catabolic cytokines such as il-1, il-6, il-17, tnf- α and prostaglan¬din e2 (pge2) are usually released during the active periods of the disease. on the other hand, matrix-metalloproteinases are destructive enzymes that released in an uncontrollable manner. host modulators were suggested to control the released of the destructive agents. immediate implant placement provides an efficient modality that shortens the dental management period. the aim behind immediate implant placement is the proper implant positioning to counteract the advanced bone resorption following extraction. periodontitis is considered an important risk factor for peri-implantitis. the pre-existing periodontitis must be treated prior to implant placement in order to avoid the bacterial accumulation in the periodontal lesions regardless the type of periodontitis. local and systemic supportive therapy is strongly recommended in order to reduce the microbial colonies and post-operative bone loss. higher rate of implant failure (peri-implantitis) has been reported in immediately placed implants when compared with the delayed conventional technique. the failure rate markedly increased with the immediate placement of implants in patients with history of periodontitis especially the aggressive form.

Eligibility criteria:
inclusion criteria: * • subjects aged above 18 years old. * patients should be free from any systemic disease. * patients with good oral hygiene * completely or partially edenthulus patients exclusion criteria: * current and former smokers. * pregnant females. * patients with systemic diseases that may interfere with periodontal condition * uncooperative patients

Keywords: aggressive periodontitis
a study to assess the disturbances in calcitonin gene in patients with gum disease and osteoporosis

Conditions: Generalized Chronic Periodontitis; Osteoporosis

Summary: osteoporosis and periodontitis are multifactorial diseases which share common risk factors.the aim of the present study is to ellucidate polymorphisms in calcitonin receptor gene? in patients with osteoporosis and periodontitis.

periodontitis is a polymicrobial inflammatory disease which includes various modifiable and nonmodifiable risk factors. the non modifiable risk factors include genetic polymorphisms like metabolism associated genetic polymorphisms ( vitamin d and calcitonin). osteoporosis is a systemic skeletal disease characterized by low bone mass and micro-architectural deterioration of bone tissue with consequent increase in bone fragility and susceptibility to fractures. bone loss is a common feature shared between periodontal disease and osteoporosis. out of all genetic factors calcitonin gene polymorphism contributes to the development of both osteoporosis and chronic periodontitis.

Eligibility criteria:
inclusion criteria: * male and female * patients aged between 35.00 year(s) to 60.00 year(s) diagnosed with osteoporosis and chronic periodontitis who are willing to participate in the study exclusion criteria: * patients who are systemically compromised and under medications such as steroids. * patients who smoke.pregnant and lactating mothers are excluded from the study

Keywords: osteoporosis chronic periodontitis calcitonin gene polymorphism
hp011-101, hp828-101, and standard care for pressure ulcers

Conditions: Pressure Ulcers

Summary: testing a drug and a device for the treatment of pressure ulcers, compared with current treatments.


Eligibility criteria:
inclusion criteria: * subjects must meet all of the following criteria to be eligible for the study: * provide informed consent, or informed assent if less than 18 years of age. * age 12 years or older, of either sex, and of any race or skin type, provided that their skin color, in the opinion of the investigator, will not interfere with the study assessments. * have a pressure ulcer ≥ 5 cm² and ≤ 100 cm² in area (measured as greatest length x perpendicular width of the area of non-blanching erythema or denuded skin, whichever is greater), and will remain hospitalized for at least three weeks. * are capable of maintaining an adequate nutritional status. * all female subjects must have a negative urinary pregnancy test. * have, within 12 weeks prior to screening, clinical laboratory test results indicating: * serum albumin ≥ 3.0 g/dl (30 g/l) * alkaline phosphatase, alt, ast, bun and serum creatinine levels \< 3x upper limit of the healthpoint normal range (refer to section 18.1.2) * hba1c ≤ 12% * hemoglobin ≥ 10 g/dl * the most recently obtained values must be evaluated against these criteria. if these values are not available from a blood sample within 12 weeks of screening, blood must be drawn at screening and these laboratory values determined. * for ulcers that will require surgical debridement prior to enrollment, the wound must be expected to remain a stage i or stage ii partial thickness wound after debridement. exclusion criteria: * subjects meeting any of the following criteria are not eligible to enter the study: * have a known hypersensitivity to any of the test articles or their components. * have received therapy with another investigational agent within thirty (30) days of screening. * are pregnant or nursing. * are currently being treated with systemic antibiotics. * have received systemic treatment with glucocorticoids for \> 10 consecutive days within 1 month prior to the start of the study. * have received chemotherapy or radiation therapy within the past 5 years. * have clinical evidence of bacterial or fungal infection of the wound per visual/clinical assessment. * have a severe burn, immunodeficiency disorder, hematologic disorder, or metastatic malignancy. * have had documented osteomyelitis in the wound area within 6 months prior to screening. * the principal investigator may declare any subject ineligible for a valid medical reason.
telerehabilitation for overactive bladder syndrome in obese women

Conditions: Overactive Bladder Syndrome

Summary: overactive bladder syndrome(oab) is a chronic medical condition which has a major influence on the quality of life in a significant amount of the population. the goal of this clinical trial study to identify the effect of telerehabilitation program on overactive bladder symptoms and metabolic health in obese women and to compare between the telerehabilitation group and the control group regarding overactive bladder symptoms and metabolic health in obese women.

overactive bladder syndrome occurs globally and affects both genders with studies indicating high prevalence in obese females. obesity brings with it not only an increased risk of cardiovascular diseases, but also urological dysfunction including overactive bladder. pilates exercise and diet can be used as ways for controlling overactive bladder symptoms and improving overall health of obese subjects. integration of telerehabilitation in the clinical practice benefits both providers and patients as well decreasing healthcare costs, so the objective of this study to determine the effect of telerehabilitation on overactive bladder symptoms and metabolic health in obese women through pilates exercise and mediterranean diet .

Eligibility criteria:
inclusion criteria: * women aged 35-45 years old * class i obesity(30-34.9kg/m2) * women will be referred by urologist with presence of overactive bladder symptoms confirmed by overactive bladder questionnaire * waist circumference more than 88 cm exclusion criteria: * history of surgical treatment of urological disease * infection of urinary tract * oncological and neurological urinary tract disease, * refusal to participate in the study
study to examine the safety and effectiveness of implanted skeletal muscle cells (cells removed from the thigh muscle) into scarred areas of heart muscle after heart attack.

Conditions: Ischemic Heart Failure; Ischemic Heart Disease; Ischemic Cardiomyopathy

Summary: study to examine the safety and effectiveness of implanted skeletal muscle cells (cells removed from the thigh muscle) into scarred areas of heart muscle after heart attack.


Eligibility criteria:
inclusion criteria: * patients recommended for coronary bypass surgery (preferably with cardiopulmonary support) * ejection fraction ≥15% and ≤35% * left ventricular myocardial infarction (mi - heart attack) ≥4 weeks prior to screening exclusion criteria: * need for a rapid surgical coronary revascularization * need for any other related cardiosurgical measure during coronary surgery (e.g. mitral valve repair or valve replacement) * patients with a left ventricular aneurysm who is a candidate for left ventricular aneurysmectomy or left ventricular reduction surgery; patient receiving left or biventricular (biv) pacing therapy for heart failure (unless the patient has stabilized after 6 or more months of this therapy) * cardiomyopathy presumed to be of non-ischemic origin
early mobilisation of the distal radius fracture

Conditions: Secondary Prevention

Summary: the goal of this clinical trial is to demonstrate the effectiveness of early therapy in 14 patients with a distal radius fracture drf resulting from injury, as the study group. assess hand function of patients who underwent surgical repair of distal radius fractures using the open reduction internal fixation method (orif), compared to their nonoperated limb, after 6 months of early rehabilitation. the main questions it aims to answer are: 1. significantly faster recovery of independence from daily activities by the patient. 2. for economic reasons, patients often expect to return to work as soon as possible. participants will be subjected to functional examination to assess hand function of patients who underwent surgical repair of distal radius fractures using the open reduction internal fixation method.


Eligibility criteria:
inclusion criteria: * age range 18-60 years * distal radius fracture * orif procedure * hand stabilisation plate (medartis) exclusion criteria: * delayed rehabilitation protocol * algodystrophy

Keywords: distal radius fracture early therapy exercise therapy
evaluation of the starflex® septal closure system in patients with a stroke or tia due to the possible passage of a clot of unknown origin through a patent foramen ovale (pfo)

Conditions: Patent Foramen Ovale; Stroke; Ischemic Attack, Transient

Summary: the primary objective of the study is to determine whether the starflex® septal closure system will safely and effectively prevent a recurrent embolic stroke/transient ischemic attack (tia) and mortality in patients with a pfo and to demonstrate superiority of the starflex® device compared to best medical therapy.


Eligibility criteria:
major inclusion criteria: * age 18-60 years inclusive. * positive contrast valsalva bubble study by trans-esophageal echocardiogram (tee) for patent foramen ovale (pfo), with or without atrial septal aneurysm. * stroke or clinically definite tia (contact study coordinator). * be able to comply with follow up over two years. * be competent to, or have a legal guardian competent to, provide informed consent following full disclosure of risks and benefits of both treatment arms by a study investigator. * venous access capable of accepting a 10f minimum vascular sheath. * have, or be willing to, discontinue hormonal based contraceptive use prior to enrollment and for the term of the study. * has cardiac anatomy based on enrollment echocardiogram that will allow for placement of the implant if randomized to the implant arm. * note: additional inclusion criteria may apply. contact study coordinator or principal investigator for details. post-randomization - device patients only * the size of the pfo (measured by indentation with a soft balloon) must be amenable to selection of a starflex device. major exclusion criteria: * carotid artery stenosis \> 50%. * intracranial stenosis \> 50% appropriate to symptoms. * complex aortic arch atheroma with high risk features for embolism * aortic arch, carotid or vertebral artery dissection. * mitral or aortic valve stenosis, vegetation, or calcification \> 5 mm mitral annular calcification (mac) thickness. * active pregnancy. * active infections (contact study coordinator). * active infective endocarditis or bacteremia. * prosthetic heart valves in any location. * anterior mi within 3 months of neurological event. * chronic atrial fibrillation * thrombus in, or occluded, venous access route. * contraindication to heparin, aspirin, clopidogrel, or warfarin, or a known medical condition that requires continuous warfarin. * patient enrolled in another investigation study where clinical endpoint interference may occur. * permanent pacemaker or inferior vena cava (ivc) filter. * serum creatinine \> 2.0 mg/dl * patients with known vasculitis or neurologic disorder. * baseline modified rankin score of 3 or more. * hypercoagulopathies requiring long-term warfarin. * note: additional exclusion criteria may apply.

Keywords: patent foramen ovale starflex closure i septal closure system stroke cerebrovascular accident transient ischemic attack heart septal defects, atrial
efficacy and immunomodulation study of simultaneous human papillomavirus/ hepatitis b (hpv/hbv) vaccination

Conditions: Human Papillomavirus Infection

Summary: rationale: in march 2009 the dutch health council advised to introduce general infant hepatitis b (hbv) vaccination in the dutch national immunization program (nip) {gezondheidsraad 2009 #16914}. to reach the anticipated health benefits earlier, a catch-up vaccination in pre-adolescents should complement the program, for girls preferably combined with human papillomavirus (hpv) vaccination at the age of 12 years. although the rationale is clear, particular aspects of combining hpv and hbv vaccination deserve further attention, especially as it has been shown that combining hpv and hbv vaccination results in reduced hbv immunogenicity/seroresponses {wheeler, bautista, et al. 2008 #17284}{pedersen 2009 #16684}. the reason for this interference is unknown, but might be due to concomitant use of different antigens and/or adjuvants, possibly skewing immunity in opposite directions. despite proven immunostimulatory effects, the use of (new) adjuvants has raised safety concern among the general public as well {israeli, agmon-levin, et al. 2009 #16924}. objective, study design and study population: in view of the observations and concerns mentioned above, further investigation into interference of hpv and hbv vaccination and adjuvant use is justified. in this context rivm propose to study single vs simultaneous hbv and hpv vaccination in 11-12-year-old girls while monitoring antigen-related and antigen-unrelated immunological parameters. the anticipated results will elucidate the extent of interference between simultaneous hpv and hbv vaccination in the target group, and guide the choice for a hbv vaccine and schedule when the hbv catch-up program is indeed introduced. furthermore, specific immunological trends post single and combined hpv and hbv vaccination will be elucidated, increasing the investigators comprehension of adjuvant use.


Eligibility criteria:
inclusion criteria: 1. female pre-adolescents born in 1998, eligible for hpv vaccination in 2011. 2. able to fulfill all study requirements. exclusion criteria: 1. previous vaccination with any licensed or experimental hpv or hbv vaccine. 2. contraindication for vaccination with cervarix®. 3. contraindication for vaccination with engerix-b®. 4. use of investigational vaccine or medication within 30 days before study 5. history of severe adverse reaction associated with a vaccine or vaccine component. 6. heart disease 7. liver disease 8. spleen removal 9. asthma 10. immune deficiency or suppression

Keywords: 1998 female birth cohort eligible for hpv vaccination in 2011 within the dutch nip
evaluating pulmonary arterial hypertension in patients with systemic sclerosis

Conditions: Systemic Sclerosis; Pulmonary Hypertension

Summary: doppler signals can be recorded from the lung parenchyma by means of a pulsed doppler ultrasound system incorporating a special signal processing package- the transthoracic parametric doppler (tpd) (echosense ltd., haifa, israel). systemic sclerosis patients often develop pulmonary vascular disease leading to pulmonary hypertension. the tpd system may provide important insight into pulmonary blood vessels characteristics by the lds (lung doppler signals) signals that are related to pulmonary hypertension. the tpd performance in detecting pah in ssc patients will be assessed in the study.


Eligibility criteria:
inclusion criteria: 1. able and willing to give signed informed consent prior to enrollment 2. male or female, ≥ 18 years of age 3. diagnosis of ssc according to 2013 acr/eular ssc classification criteria (van den hoogen 2013): score ≥ 9. 4. patients with rhc data available from measurement within 3 weeks prior to tpd assessment 5. no change in or initiation of pah specific therapy between the last rhc and tpd exclusion criteria: 1. people unable or unwilling to give informed consent. 2. pcwp or lvedp \> 15 mmhg 3. any ph etiology outside group 1 (dana point, 2008) 4. pregnant women 5. patients having severe chest wall deformity

Keywords: systemic sclerosis pulmonary hypertension lung doppler signals
does wearing tetra-grip improve arm function in children diagnosed with neonatal brachial plexus palsy?

Conditions: Neonatal Brachial Plexus Palsy

Summary: this study evaluates the effect of wearing a tetra-grip on the affected arm of children with neonatal brachial plexus palsy. half of the participants will have tetra-grip applied to the arm, while the other half will not have it applied to the arm.

tetra-grip is a tubular elastic support bandage that provides both compression and support. previous studies have shown that by applying neoprene or athletic tape to a joint on individuals with poor proprioception or a history of joint injury, such modalities enhanced their proprioceptive recognition via stimulation of mechanoreceptors responding to skin stretch and compression during joint motion. as a result, patients have greater kinesthetic and joint position awareness of their limb.

Eligibility criteria:
inclusion criteria: * 3 - 7 years old * male or female * non-dominant upper extremity brachial plexus injury exclusion criteria: * botox injections to the affected extremity within the past 3 months * severe muscle contractures of affected extremity that restricts functional use of the arm and hand * concurrent cerebral palsy

Keywords: tetra-grip assisting hand assessment